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The COVID-19 pandemic has entailed a world health 
emergency, without precedent in the past century, that 
has already cost more than three million lives.1 This box 
briefly describes how the disease has developed since its 
beginnings, the international differences observed in its 
incidence and the outlook for its future course.
The origin of the disease is still uncertain, but the first 
cases were documented in the Chinese city of Wuhan in 
mid-December 2019. During the first two months of 2020, 
when China was already tackling a first-order health crisis, 
the virus spread progressively through the rest of the 
northern hemisphere. Infections having surpassed 
100,000 in more than 100 countries, the World Health 
Organisation declared the disease a pandemic on 11 
March 2020 (see Chart 1.1). 
In March and April, its rapid spread posed a huge 
challenge to highly saturated health systems, leading to 
the introduction of stringent containment measures, 
practically unprecedented in peacetime, such as home 
confinement (see Chart 1.2).2 As a consequence, the 
spread of the virus slowed progressively, leading to a 
gradual easing of restrictions in most advanced economies 
from the second half of the second quarter. Meanwhile, 
the virus was spreading through the emerging economies, 
with particular virulence in Latin America. 
In the summer, the incidence of the pandemic was 
relatively limited in the northern hemisphere, but infections 
and deaths rose progressively from September with much 
greater geographical heterogeneity than in the first wave. 
At global level, this new wave, which has cost many more 
lives than the first one, peaked in February 2021 (see 
Chart  1.3). Since then, the pandemic containment 
measures, which had been strengthened again during the 
autumn, have been intermittently eased, as progress has 
been made with vaccination. In recent weeks there has 
been a rise in fatalities in the emerging economies, 
especially in India, where vaccination is lagging.
Against a background of notably heterogeneous 
containment measures, the incidence of the pandemic 
across geographical areas, as regards its timing, 
magnitude and persistence, has been very uneven, as can 
be seen, for example, in deaths per capita (see Chart 2). 
In the first few months, given the initial experience of 
China,3 the most widespread approach in the advanced 
economies was to impose general lockdowns and severe 
restrictions on personal mobility and on activity in certain 
sectors.4 However, some countries, such as South Korea, 
decided to focus their efforts on mass testing and 
thorough contact tracing.5 Subsequently, other countries 
(such as Japan, New Zealand and Australia) have followed 
a similar strategy and, with very strict controls on spread 
in the community, have managed to recover some degree 
of normal social activity. By contrast, certain other 
economies (such as Sweden, the United States and Brazil) 
opted for less restrictive containment measures from a 
normative perspective.6 
Generally speaking, after the experience of the first wave, 
a broader range of measures was used to address the 
health crisis, and these tended to be more focused on 
specific areas or activities to try to minimise social and 
economic disruption. In any event, even in the most 
extreme episodes, the tightening of the pandemic 
containment measures during the second wave did not 
reach the level of stringency seen in the first phase. At the 
same time, regardless of the reaction of the authorities, 
there was also notable adaptation by households and 
firms. Indeed, the general public have been adapting their 
habits; for example, there has been a voluntary reduction 
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Department Working Papers, No 1633. 
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SOURCES: World Bank, Bloomberg, Duke Global Health Innovation Center, Johns Hopkins University - Coronavirus Resource Center, Our World in
Data, COVID-19 INED, COVerAGE-DB, Reuters, Oxford COVID-19 Government Response Tracker and Rungcharoenkitkul (2021).
a Asia includes Russia.
b The United Kingdom data are for England and Wales; the euro area data are for Germany, Spain, France and Italy. 
c Vaccines acquired under the COVAX initiative as a percentage of the population of emerging countries.
d Scenarios considered by Rungcharoenkitkul (2021). The "baseline" scenario assumes linear progress in the rate of vaccination until all the doses ordered 
have been exhausted at the end of 2021. Under the "slow vaccination" scenario vaccination proceeds at a third of the rate under the "baseline"scenario. 
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in social interaction and mobility,7 in some economies 
with the support of firms, through their expansion of 
teleworking, digitalisation and e-commerce.
The determinants of the heterogeneity in the incidence of 
the virus and mortality across countries and geographical 
areas remain uncertain. The literature points to a set of 
factors that may partly account for it. For example, some 
studies associate greater spread of the disease with 
certain structural characteristics linked to personal 
interaction patterns, climate,8 population concentration 
and the productive system (the latter on account of the 
different importance of the activities that can benefit from 
teleworking and of those that involve a high degree of 
human contact). Other possible reasons for the 
asymmetric impact of the pandemic by country include 
the demographic structure of the population, given the 
higher mortality in older age groups (see Chart 1.4), the 
quality of health systems9 and the proportion of the 
population that has acquired immunity having recovered 
from the illness or been vaccinated. A second group of 
factors is more related to sociological characteristics. For 
example, societies with customs involving more physical 
contact can be expected to have greater difficulty 
containing the spread of the virus, while those with prior 
experience of this type of disease should be better 
prepared.10 As already mentioned, the selection of the 
health strategy in each country may also have affected 
the heterogeneity observed in the incidence of the 
pandemic.
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 7  See W. Maloney and T. Taskin (2020), “Determinants of Social Distancing and Economic Activity during COVID-19: A Global View”, Policy Research 
Working Paper Series 9242, World Bank. 
 8  See C. Ghirelli, A. González, J. L. Herrera, and S. Hurtado (2021), Weather, mobility and the evolution of the Covid-19 pandemic, Working Papers, 
No 2109, Banco de España.
 9  See Sussman (2020), “Time for Bed(s): Hospital Capacity and Mortality from COVID-19”, Covid Economics, 11. 
10  See A. Buesa, J. J. Pérez and D. Santabárbara (2021), “Awareness of pandemics and the impact of COVID-19”, Economics Letters, forthcoming 
and Working Papers, Banco de España, forthcoming.
SOURCE: WHO.
a Each shaded area corresponds to a 21-day interval.
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The availability of various effective vaccines for COVID-19, 
within months of the pandemic emerging, is considered a 
medical milestone and key to overcoming the health 
crisis.11 In particular, gradual immunisation of the 
population is expected to be accompanied by a reduction 
in mortality, the lifting of containment measures and a 
gradual return to normal of social and economic activity. 
The worldwide vaccination campaign was launched in 
December 2020 and, so far, 2% of the global population 
has been immunised. In addition, there are those who 
have some natural immunity as a result of having had the 
disease. Also, medical treatments have been developed 
that are reducing mortality and the after effects of the 
disease. Countries have already acquired sufficient 
vaccines to vaccinate more than 60% of the world 
population, which could be compatible with control over 
the disease this year, as long as they do not lose their 
effectiveness.12 However, access to vaccines in advanced 
economies is much greater than in other countries despite 
the initiatives taken to boost the supplies to developing 
countries13 (see Chart 1.5). Vaccine roll-out at global level 
is highly uneven across countries, owing to the supply 
contracts with pharmaceutical companies, the logistical 
challenges of the different types of vaccines acquired and 
the capacity of health systems to administer them to the 
most vulnerable groups.
This baseline scenario, under which the disease is 
controlled this year, is uncertain, however, and a global 
medical solution may be delayed (see Chart 1.6). Thus, on 
one hand, it is possible that the vaccination plans are 
optimistic and may not be fulfilled. On the other hand, of 
particular concern is a possible loss of immunity due to 
the emergence of new variants of the virus – some of 
which may be more contagious or lethal – that reduce the 
effectiveness of the current vaccines and naturally 
acquired immunity. In this respect, virus mutations that 
result in a loss of immunity may be encouraged by 
excessively cautious vaccination strategies that delay 
complete immunity or that cover only part of the world 
population.14 This scenario of heightened persistence of 
the pandemic may entail the need for intermittent 
containment measures.15 Finally, when the pandemic is 
over, the disease could become seasonal, requiring 
regular prevention and vaccination drives.
Against this background, it is crucial that the authorities 
continue to strengthen health systems, in particular their 
preventive and rapid response capabilities, as well as the 
supply of vaccines and other medical equipment. In a global 
setting, for personal mobility to return to normal, international 
cooperation is also required, to ensure universal access to 
vaccines and the medical treatments available. 
11  Several effective COVID-19 vaccines have been developed and clinically tested in record time (less than a year). This rapidity, facilitated by the 
financing available and the speeding up of approval processes, has also been a consequence of past experience in the development of vaccines 
against other recent diseases (e.g. SARS and MERS). For further information, see S. Su, L. Du and S.  Jiang (2020), “Learning from the past: 
development of safe and effective COVID-19 vaccines”, Nature Reviews Microbiology, 19, 211–219. 
12  See Rungcharoenkitkul (2021), “Macroeconomic consequences of pandexit”, Working Papers, No 932, BIS. 
13  Notably, the COVAX (Covid-19 Vaccines Global Access) initiative, which aims for fair access to vaccines through a joint purchase mechanism for 
distribution among the emerging countries.
14  See O. J. Wouters, K. C. Shadlen, M. Salcher-Konrad, A. J. Pollard, H. J. Larson, Y. Teerawattananon and M. Jit (2021), “Challenges in ensuring 
global access to COVID-19 vaccines: production, affordability, allocation, and deployment”, The Lancet. 
15  Experience with other diseases suggests there is a risk it will become chronic. See D. Morens and A. Fauci (2020), “Emerging Pandemic Diseases: 
How We Got to COVID-19”, Cell 182(5).
